Endocrine cardiomyopathy in cushing syndrome: Response to cyclic GMP PDE5 inhibitOrs
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing’s Syndrome-Endocrine cardiomyopathy in cushing syndrome: Response to cyclic GMP PDE5 inhibitOrs - Endocrine cardiomyopathy in cushing syndrome: Response to cyclic GMP PDE5 inhibitOrs Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Ne ...
Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs
Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Ne ...